Cepheid (CPHD) Price Target Raised to $52.00 at Barclays PLC
Cepheid (NASDAQ:CPHD) had its target price upped by investment analysts at Barclays PLC from $36.00 to $52.00 in a research note issued to investors on Wednesday. The firm currently has an “equal weight” rating on the stock. Barclays PLC‘s target price would suggest a potential downside of 1.23% from the company’s current price.
Several other analysts also recently weighed in on the stock. Jefferies Group lifted their target price on shares of Cepheid from $28.00 to $34.00 and gave the company a “hold” rating in a report on Wednesday, August 17th. Canaccord Genuity reiterated a “hold” rating and issued a $32.00 target price on shares of Cepheid in a report on Wednesday, June 29th. Piper Jaffray Cos. downgraded shares of Cepheid from an “overweight” rating to a “neutral” rating in a report on Tuesday. Zacks Investment Research upgraded shares of Cepheid from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a research note on Tuesday, June 28th. Finally, Needham & Company LLC downgraded shares of Cepheid from a “buy” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $41.58.
In other news, VP Scott A. Campbell sold 746 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $36.71, for a total value of $27,385.66. Following the completion of the sale, the vice president now directly owns 10,721 shares of the company’s stock, valued at $393,567.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.16% of the stock is currently owned by insiders.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/cepheid-cphd-price-target-raised-to-52-00-at-barclays-plc.html
Other large investors have made changes to their positions in the company. BlackRock Institutional Trust Company N.A. raised its position in shares of Cepheid by 2.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,829,588 shares of the company’s stock worth $61,035,000 after buying an additional 36,476 shares during the period. Kornitzer Capital Management Inc. KS raised its position in shares of Cepheid by 4.2% in the second quarter. Kornitzer Capital Management Inc. KS now owns 1,273,705 shares of the company’s stock worth $39,166,000 after buying an additional 51,870 shares during the period. Norges Bank purchased a new position in shares of Cepheid during the fourth quarter worth about $32,233,000. Granahan Investment Management Inc. MA raised its position in shares of Cepheid by 63.6% in the first quarter. Granahan Investment Management Inc. MA now owns 847,900 shares of the company’s stock worth $28,286,000 after buying an additional 329,500 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Cepheid by 1.7% in the first quarter. Geode Capital Management LLC now owns 527,968 shares of the company’s stock worth $17,612,000 after buying an additional 8,809 shares during the period. 95.60% of the stock is owned by institutional investors and hedge funds.
Cepheid (NASDAQ:CPHD) traded up 0.23% during trading on Wednesday, hitting $52.65. The company had a trading volume of 6,641,056 shares. The firm’s 50 day moving average is $36.08 and its 200-day moving average is $32.23. Cepheid has a 52-week low of $25.09 and a 52-week high of $53.19. The stock’s market capitalization is $3.84 billion.
Cepheid (NASDAQ:CPHD) last posted its earnings results on Thursday, July 28th. The company reported $0.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.19. The company earned $146 million during the quarter, compared to analyst estimates of $145.82 million. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.06) EPS. On average, equities analysts forecast that Cepheid will post $0.33 earnings per share for the current year.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
To view Barclays PLC’s full report, visit Barclays PLC’s official website.
Receive News & Ratings for Cepheid Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cepheid and related companies with MarketBeat.com’s FREE daily email newsletter.